Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD22-targeted CAR-T cells (PersonGen)
- Development stage
- Unknown
- Lead developer
- PersonGen BioTherapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD22-targeted CAR-T cells (PersonGen) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. for the treatment of various CD22-positive B-cell malignancies. The therapy involves the ex vivo genetic modification of a patient's own T cells to express a CAR that specifically targets CD22, a cell surface glycoprotein expressed on mature B cells and most B-cell lineages. Upon re-infusion into the patient, these engineered T cells recognize and bind to CD22-expressing tumor cells, leading to T-cell activation and targeted cytotoxicity. This investigational biologic is currently being evaluated in Phase 1 clinical trials for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and several types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma.
- Other names
- CD22 CAR-TCD-22 CAR-TCD 22 CAR-TPersonGen CD22 CAR-TAutologous CD22-targeted CAR-T cells
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD22-targeted CAR-T cells (PersonGen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD22-targeted CAR-T cells (PersonGen).